Disease · MONDO_0019781
Trials50
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 20 of 50
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00626990 | Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH) | Phase 3 | 751 | 2023-09-11 | Brain and Central Nervous System Tumors | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00411619 | Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex | Phase 1/2 | 28 | 2014-10-20 | Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT03032484 | TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma | Phase 2 | 25 | 2023-06-15 | Astrocytoma | BEVACIZUMAB, DENIFANSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT01188096 | A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas | Phase 2 | 23 | 2023-04-03 | Brain Tumors | HILTONOL | Its record names the disease | ClinicalTrials.gov |
| NCT00003468 | Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma | Phase 2 | 11 | 2016-11-10 | Low Grade Astrocytomas | ANTINEOPLASTON A10 | Its record names the disease | ClinicalTrials.gov |
| NCT00003471 | Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma | Phase 2 | 7 | 2017-12-13 | Low-Grade Astrocytoma, Nos | ANTINEOPLASTON A10 | Its record names the disease | ClinicalTrials.gov |
| NCT03906448 | FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma | Phase 2 | 1 | 2021-09-23 | Astrocytoma, Grade II, Astrocytoma, Grade III | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT07448480 | Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas | 1,000 | Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, Pleomorphic Xanthoastrocytoma | BEVACIZUMAB, CARBOPLATIN, IRINOTECAN, NIMUSTINE | Its record names the disease | ClinicalTrials.gov | ||
| NCT06809322 | Vorasidenib Maintenance for IDH Mutant Astrocytoma | Phase 3 | 468 | IDH-mutant Grade 2 or 3 Astrocytoma | VORASIDENIB | Its record names the disease | ClinicalTrials.gov | |
| NCT07215910 | Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | Phase 3 | 408 | Astrocytoma, IDH-Mutant, Grade 3 | TEMOZOLOMIDE, VORASIDENIB | Its record names the disease | ClinicalTrials.gov | |
| NCT05303519 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Phase 3 | 365 | Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, IDH-Mutant, Grade 2, Oligodendroglioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted | SAFUSIDENIB | Its record names the disease | ClinicalTrials.gov | |
| NCT02796261 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients | Phase 3 | 343 | Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma | EFLORNITHINE, LOMUSTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00028795 | Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma | Phase 2 | 170 | Brain and Central Nervous System Tumors | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00003745 | Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas | Phase 2 | 125 | Sarcoma | TOPOTECAN | Its record names the disease | ClinicalTrials.gov | |
| NCT02567539 | Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma | Not applicable | 88 | Recurrent High Grade Glioma | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT05518994 | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma | Phase 2 | 70 | Astrocytoma of Brain | BEVACIZUMAB, SINTILIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03893903 | AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma | Phase 1 | 69 | Malignant Glioma | AVELUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05879367 | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma | Phase 1 | 66 | Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM, Astrocytoma, Astrocytoma, IDH-Mutant | EFLORNITHINE, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT03782415 | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma | Phase 1/2 | 64 | Glioblastoma, Recurrent Glioblastoma, GBM, Newly Diagnosed Glioblastoma | IBUDILAST, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06969352 | A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study) | Not applicable | 62 | Gliomas | VORASIDENIB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019781/trials